PUBLIC COMPANY
save$AKTSAktis Oncology, Inc.
$AKTS24.50-1.72%Boston, MA, USupdated 2h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Apr 15, 26grantGormley Glenn · director37,866 sh
🐶 Hiring Signal
News
- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.biospace · 20d ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that